Work

Supplemental Figure 1 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Year: 2023

Type: supplementary-materials

Abstract: Enzalutamide resistant VCaP prostate cancer cells.

DOI: 10.1158/1541-7786.22514320

Authors: Irfan A. Asangani, Kari Wilder-Romans, Vijaya L. Dommeti, Pranathi M. Krishnamurthy, Ingrid J. Apel, June Escara-Wilke, Stephen R. Plymate, Nora M. Navone, Shaomeng Wang, Felix Y. Feng, Arul M. Chinnaiyan

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362613746

Cites:

Cited by:

Related to: 10